Supriya Lifescience Limited · NSE:SUPRIYA
Supriya Lifescience — Q3 FY25 Earnings Presentation
36 slides from Supriya Lifescience's earnings presentation, Jan 24, 2025
Slide 1: Exchange cover letter: Investor Presentation
Date: January 24, 2025 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543434 Scrip Symbol: SUPRIYA Dear Sir/Madam, Subject: Investor Prese
Slide 2: Investor Presentation | Q3 & 9M FY25
SUPRIYA LIFESCIENCE LTD. Investor Presentation | Q3 & 9M FY25
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Q3 & 9M FY25 Highlights
M FY25 Highlights cS SUPRIYA LIFESCIENCE LTD.
Slide 5: Q3 FY25 Highlights - Regional Performance
Q3 FY25 Highlights (in INR Mn) Revenue EBITDA PBT PAT Quarterly Rs. 1856.5 Mn Rs. 659.5 Mn Rs. 625.8 Mn Rs. 467.8 Mn 33% YoY 59% YoY 56% YoY 57% YoY Business Mix Revenue Contribution – By Region Regional Performance 42% 42% Q3 FY24 38% 40% 32% 31% Q2 FY25 Q3 FY25 19% 21% 8% 6% 5% 5% 3% 4% 5% Asia Eu
Slide 6: 9M FY25 Highlights - Regional Performance
9M FY25 Highlights (in INR Mn) Revenue EBITDA PBT PAT Quarterly Rs. 5,123.8 Mn Rs. 1,932.1 Mn Rs. 1,844.2 Mn Rs. 1,375.8 Mn 24% YoY 64% YoY 64% YoY 67% YoY Business Mix Revenue Contribution – By Region Regional Performance 41% 43% 9M FY24 40% 32% 9M FY25 17% 9% 6% 4% 4% 4% Asia Europe LAC North Amer
Slide 7: Q3 & 9M FY25 - Y-o-Y Highlights
Q3 & 9M FY25 - Y-o-Y Highlights (in INR Mn) Revenue EBITDA PBT PAT +24% +64% +64% +67% 5,123.8 1,932.1 1,844.2 1,375.8 4,121.9 +33% 1,174.7 +59% 1,125.2 +56% 821.8 +57% 1,856.5 659.5 625.8 467.8 1,400.7 414.9 401.0 297.8 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3
Slide 8: Business Mix Revenue Contribution - By Therapy
Business Mix Revenue Contribution – By Therapy Performance of the Therapeutic Areas Y-o-Y 60% 49% 15% 14% 12% 10% 7% 4% 5% 4% 2% 1% Analgesic/Anesthetic Anti-histamine Vitamins Anti-Asthmatic Anti-allergic Anti-hypertensive Q3FY24 Q3FY25 7 Q3 FY25 Earnings Presentation
Slide 9: Q3 & 9M FY25 Profit & Loss Statement
Q3 & 9M FY25 Profit & Loss Statement Particulars (in INR Mn) Q3 FY25 Q3 FY24 Y-o-Y Q2 FY25 Q-o-Q 9M FY25 9M FY24 Y-o-Y Revenue from Operations 1,856.5 1,400.7 33% 1661.0 12% 5,123.8 4,121.9 24% Cost of Materials Consumed 626.8 448.4 615.8 1,799.9 1,430.7 Changes in Inventories of Finished Goods and
Slide 10: Company Overview
SUPRIYA LIFESCIENCE LTD.
Slide 11: Business Overview
Business Overview Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics 40+ APIs 120+ Countries 33,000 Sq.mts 932 KLPD Niche product basket Diversified operations with presence Manufacturing facility spread across Reactor capacity WHO-GMP, Written Confirmation, IS
Slide 12: Journey So Far
Journey So Far 2020 2021 2022 2023 2024 Third time CEP granted for Pentoxifylline, Esketamine CEP (Certificate of The Company commenced ANVISA Approval USFDA approval Hydrochloride and Salbutamol Sulphate; suitability ) renewed for operations at its Granted NMPA approval granted; Health Canada Pheni
Slide 13: Backward Integrated Business Model
Backward Integrated Business Model Cost-competitive Supply Security Low Price Risk In-House Processes Structure Steady supply of essential raw Protection against market Less Dependence On External Increasing margins materials fluctuations Parties 15 products are backward integrated* in following the
Slide 14: Diversified Geographic Presence
Diversified Geographic Presence For key products we are seeing good traction in untapped regulated markets of North America For Anaesthetic therapy 3 ANDA projects have been initiated and we are also working on ANDA projects for Anti Hypertensive and Vitamins Presence in 86+ Countries Across Globe 1
Slide 15: Diversified Revenues with Extensive Global Presence
Diversified Revenues with Extensive Global Presence Significant export presence, with low dependence on a … with customer concentration specific geography Export sales, as a % of revenue from operations Share of top 10 customers, as a % of revenue from operations 77% 76% 80% 79% 47% 49% 45% 40% FY21
Slide 16: Advanced Manufacturing and R&D Capabilities
Advanced Manufacturing and R&D Capabilities o Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, dedicated areas for engineering maintenance, 5 9 warehouse, raw materials, packaging materials and Manufacturing Blocks Clean Rooms finished goods stores o Newly com
Slide 17: R&D Capabilities
R&D Capabilities Supported by R&D driven mindset DSIR approved facility 15* 9* 4* • A team of 60+ scientists primarily focused on API process development across the value chain DMFs CEPs CEPs in process • Strong portfolio in key therapeutic areas, including anesthetics, anti-asthmatics, antihistamin
Slide 18: CMO Capabilities
CMO Capabilities • State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation • Complete support in validation, stability, & compilation of dossiers • Dedicated technology transfer team is periodically trained to enhance skill
Slide 19: Recently Commissioned State of The Art E Block
Recently Commissioned State of The Art E Block • Capacity: 335 KLPD • Large volume equipment – multipurpose synthesis with focus on backward integration capabilities • Closed systems using gravity flow equipped with process control system. 18 Q3 FY25 Earnings Presentation
Slide 20: FDF Facility ready for commissioning at Ambernath
FDF Facility ready for commissioning at Ambernath • The site spans 5,000 sqm, with 70% of the area constructed, located at Plot No. N-60, Facility Location Additional Ambernath MIDC, District Thane, Maharashtra, India (PIN: 421506) • Situated 60 km from Nhava Sheva Port (New Mumbai) and 50 km from M
Slide 21: Complex Chemistries & Reaction
Complex Chemistries & Reaction Focus on uniform manufacturing standards to achieve standardised product quality across markets High vacuum distillations … across varied class of reactions Ability to handle complex chemistries.. Cyclisation Grignard reaction • Simple to highly complex chiral molecule
Slide 22: Regulatory Achievements
Regulatory Achievements Strong focus on compliance guided by ethical approach • Our motto is to consistently meet the stringent requirements of regulatory bodies • Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and managing regulatory queries
Slide 23: Number of API's Under Pipeline
Number of API’s Under Pipeline API’s Under Pipeline Status USDMF’s 18 API’s Submitted CEP 9 API’s Granted USDMF 2 API Submission Under Progress CEP 4 API’s Under Progress CADIFA Brazil 10 API’s Granted 22 Q3 FY25 Earnings Presentation
Slide 24: Awards & Accreditation
Awards & Accreditation 2009 2010 2016 Certificate of Excellence for outstanding Export Special Recognition National Award for Research and Export House for the Year for 2015-16 awarded by Directorate of Performance in the product group Chemicals, Drugs, Development awarded by Ministry of Micro Small
Slide 25: Key Management Team
Key Management Team Satish Wagh Executive Chairman & WTD • B.Sc. from R.D National College and W.A. Science College, University of Bombay, Mumbai & an honorary Ph.D. in entrepreneurship from Faculty of Management Studies, National American University • Director on the boards of Supriya Medi-Chem Pri
Slide 26: EHS
EHS Environment Health Safety • Regular and strict monitoring to produce highest • Clean, safe and healthy working environment for our • Committed to safe and accident-free operations in all efficiency in pollution control all employees our establishments • Safeguarding our employees and facilities
Slide 27: CSR & Social Work
CSR & Social Work We believe true corporate citizenship is rooted in giving back to society, recognizing our responsibility extends beyond business paradigm • Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from the employees to the stude
Slide 28: Historical Financial Performance
Historical Financial Performance
Slide 29: Consistent & Strong Financial Performance
Consistent & Strong Financial Performance Robust revenue growth Capex Spend … and, focus on profitability 1,457 +13.0% +15.6% 5,703.7 2,140 5,300.5 1,078 4,609.4 949 1,732 1,730 3,911.9 1,518 1,236 1,289 1,191 3,195.4 1,063 899 734 179 94 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 F
Slide 30: Working Capital Break-up
Working Capital Break-up Inventory Receivables 233 73 71 206 63 61 172 165 53 130 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 Payables Net Working Capital 113 235 194 196 79 75 59 124 49 105 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 29 Q3 FY25 Earnings Presentation
Slide 31: Summary Statement of Profit and Loss
Summary Statement of Profit and Loss Particulars (in INR Mn) FY24 FY23 FY22 FY21 Total Revenue 5,703.7 4,609.4 5,300.5 3,912.4 Cost of Materials Consumed 1,914.3 1,873.2 1,988.3 1,405.7 Changes in Inventories of Finished Goods and Work in Progress 303.1 -65.1 -30.3 -124.5 Gross Profit 3,486.3 2,801.
Slide 32: Summary Statement of Assets and Liabilities
Summary Statement of Assets and Liabilities Particulars (in INR Mn) Mar 24 Mar 23 Mar 22 Mar 21 Particulars (in INR mn) Mar 24 Mar 23 Mar 22 Mar 21 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Equity share capital 161.0 161.0 161.0 146.4 (i) Property, plant and equipment 3,037.0 2,551
Slide 33: Summary Statement of Cashflow
Summary Statement of Cashflow Particulars (in INR Mn) FY24 FY23 FY22 FY21 Cash Flow from Operating Activities Profit before Tax 1,656.9 1,234.9 2,072.5 1,673.9 Adjustment for Non-Operating Items 24.0 72.0 68.7 53.1 Operating Profit before Working Capital Changes 1,680.9 1,306.8 2,141.2 1,727.0 Chang
Slide 34: Future Outlook
SUPRIYA Outlook cS LIFESCIENCE LTD. 2
Slide 35: Future Outlook
Future Outlook Two new R&D centres CMO/CDMO space • The future of the company is deeply rooted in R&D, with significant progress made to • Company understands large scale special chemical manufacturing and has experience in enhance research capabilities handling hazardous complex process chemistry 1
Slide 36: Thank You
Supriya Lifescience Limited CIN: L51900MH2008PLC180452 Mr. Krishna Raghunathan - Chief Financial Officer cfo@supriyalifescience.com www.supriyalifescience.com Orient Capital (a division of Link Group) Mr. Irfan Raeen Ms. Prachi Ambre +91 97737 78669 +91 83559 85370 irfan.raeen@linkintime.co.in prach